GlobalData has estimated that the global Crohn’s Disease therapeutics market was worth $4.4 billion in 2012
GlobalData estimates that the global GVHD therapeutics market was worth $261.6m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 11.3% to reach $615.1m by 2018.
Bell Potter has previously noted (Feb 2014) in one of their research reports that GVHD could be a US$300 - $600m and Crohns Disease a US$2.4bn market. In Bell Potters 12 month price target (approx. $9 +), Prochymal has not been factored into their valuation and noted as such -
Based on recent 29/4/14 ASX release ..and CNBC interviews (all posted before) SI quite excited by the potential of Prochymal...in fact MSB's evaluation of the Osiris data at the time , was a major reason why they outlaid $50M + in acquiring their MSC technology.
On 28/5/2014 ASX release about MSB also accelerating there manufacturing plans in Singapore also made reference to Prochymal.
Please DYOR and GLTAH.
- Forums
- ASX - By Stock
- Prochymal
GlobalData has estimated that the global Crohn’s Disease...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.02 |
Change
-0.045(4.23%) |
Mkt cap ! $1.216B |
Open | High | Low | Value | Volume |
$1.04 | $1.04 | $1.00 | $1.195M | 1.168M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 11459 | $1.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.03 | 33404 | 14 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 115919 | 1.015 |
12 | 139612 | 1.010 |
9 | 102854 | 1.005 |
7 | 155444 | 1.000 |
3 | 26400 | 0.995 |
Price($) | Vol. | No. |
---|---|---|
1.020 | 10037 | 3 |
1.025 | 56223 | 13 |
1.030 | 89963 | 8 |
1.035 | 44651 | 10 |
1.040 | 48336 | 6 |
Last trade - 10.35am 04/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |